News | November 23, 2024
Merck recommends rejection of TRC Capital’s “Mini-Tender” Offer
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Dr. Muthu was last associated with Mankind Pharma
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
The product will be manufactured at Lupin’s Somerset facility in the US
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Subscribe To Our Newsletter & Stay Updated
